Northland Securities Analysts Give Intrexon Corporation (XON) a $30.00 Price Target
Intrexon Corporation (NYSE:XON) has been assigned a $30.00 price objective by research analysts at Northland Securities in a research report issued to clients and investors on Monday. The firm presently has a “buy” rating on the biotechnology company’s stock. Northland Securities’ price objective indicates a potential upside of 38.57% from the stock’s previous close.
Several other analysts have also weighed in on the company. BidaskClub lowered Intrexon Corporation from a “hold” rating to a “sell” rating in a research note on Friday. Zacks Investment Research lowered Intrexon Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. Intrexon Corporation currently has an average rating of “Hold” and a consensus price target of $40.50.
Shares of Intrexon Corporation (XON) traded up 0.2711% on Monday, reaching $21.7087. 239,726 shares of the company traded hands. The company’s market capitalization is $2.60 billion. The firm’s 50 day moving average is $23.55 and its 200 day moving average is $22.08. Intrexon Corporation has a one year low of $18.41 and a one year high of $32.90.
Intrexon Corporation (NYSE:XON) last released its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.04. The business had revenue of $53.70 million during the quarter, compared to analyst estimates of $49.08 million. Intrexon Corporation had a negative net margin of 76.32% and a negative return on equity of 21.19%. The business’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same period last year, the business earned ($0.55) earnings per share. Analysts expect that Intrexon Corporation will post ($0.91) earnings per share for the current fiscal year.
Hedge funds have recently made changes to their positions in the stock. Federated Investors Inc. PA acquired a new stake in Intrexon Corporation during the second quarter worth about $172,000. Pacer Advisors Inc. increased its position in Intrexon Corporation by 21.6% in the first quarter. Pacer Advisors Inc. now owns 7,352 shares of the biotechnology company’s stock worth $146,000 after buying an additional 1,305 shares during the period. SG Americas Securities LLC purchased a new position in Intrexon Corporation during the first quarter worth $164,000. Cullinan Associates Inc. purchased a new position in Intrexon Corporation during the second quarter worth $201,000. Finally, Biondo Investment Advisors LLC purchased a new position in Intrexon Corporation during the first quarter worth $214,000. 84.38% of the stock is currently owned by hedge funds and other institutional investors.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.